Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Forbes contributors publish independent expert analyses and insights. I write about business model strategy and execution across healthcare.

Late last year, doc­tors in­ject­ed an ex­per­i­men­tal CRISPR ther­a­py in­to the brain of a 9-year-old boy with a rare neu­rode­vel­op­men­tal con­di­tion that can cause in­tel ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shanghai-based VelaVigo has been busy. The biotech granted Avenzo Therapeutics ex-China rights to a Nectin4xTROP2 bispecific antibody-drug conjugate in November, netting up to $50 million in ...

The new company is led by CEO Caroline Loew, a biotech veteran with experience at Blympse Bio, Bristol-Myers Squibb, and Merck. Mural Oncology has offices in Dublin, Ireland, but its primary ...

In a major leap for the future of lab-grown meat, researchers at the University of Tokyo have developed a new bioreactor that mimics a circulatory system to grow realistic cuts of chicken muscle—no ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against ...

I often refer to Regeneron as a “Biotech Juggernaut” because it seems like they have similar strengths to the comic book character. The company appears to have unstoppable momentum thanks to a ...

After San Francisco biotech company Third Harmonic Bio slashed its staff by half in February, it’s now taking a more drastic step. The inflammatory disease research company’s directors have ...

However, biotech companies have not given up on finding a treatment for HIV. The biotech industry has made progress in both treatment and prevention, and heavyweights like Gilead, ViiV Healthcare, and ...

The rally is fuelled by the surprise pause in reciprocal tariffs which continued today led by the exemption on electronics goods also. The performance was broad-based, with sectors like financials, ...